Literature DB >> 25448321

[Therapy of intermediate uveitis].

D Doycheva1, C Deuter, M Zierhut.   

Abstract

Intermediate uveitis is a form of intraocular inflammation in which the vitreous body is the major site of inflammation. Intermediate uveitis is primarily treated medicinally and systemic corticosteroids are the mainstay of therapy. When recurrence of uveitis or side effects occur during corticosteroid therapy an immunosuppressive treatment is required. Cyclosporine A is the only immunosuppressive agent that is approved for therapy of uveitis in Germany; however, other immunosuppressive drugs have also been shown to be effective and well-tolerated in patients with intermediate uveitis. In severe therapy-refractory cases when conventional immunosuppressive therapy has failed, biologics can be used. In patients with unilateral uveitis or when the systemic therapy is contraindicated because of side effects, an intravitreal steroid treatment can be carried out. In certain cases a vitrectomy may be used.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448321     DOI: 10.1007/s00347-014-3201-2

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  52 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Immunosuppressants used in a steroid-sparing strategy for childhood uveitis.

Authors:  Claude Speeg Schatz; Jean Louis Uzel; Laurent Leininger; Stéphanie Danner; Joëlle Terzic; Michel Fischbach
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2007 Jan-Feb       Impact factor: 1.402

3.  Impact of macular edema on visual acuity in uveitis.

Authors:  Charlotte W T A Lardenoye; Bram van Kooij; Aniki Rothova
Journal:  Ophthalmology       Date:  2006-08       Impact factor: 12.079

Review 4.  Interferon-α therapy in noninfectious uveitis.

Authors:  Christoph Deuter; Nicole Stübiger; Manfred Zierhut
Journal:  Dev Ophthalmol       Date:  2012-04-17

5.  Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis.

Authors:  Ivan Foeldvari; Angela Wierk
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

6.  Mycophenolate sodium for immunosuppressive treatment in uveitis.

Authors:  Christoph M E Deuter; Deshka Doycheva; Nicole Stuebiger; Manfred Zierhut
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

Review 7.  Special considerations in the evaluation and management of uveitis in children.

Authors:  Gary N Holland; E Richard Stiehm
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

8.  Intravitreal bevacizumab for treatment of uveitic macular edema.

Authors:  Miguel Cordero Coma; Lucia Sobrin; Sumru Onal; William Christen; C Stephen Foster
Journal:  Ophthalmology       Date:  2007-03-23       Impact factor: 12.079

9.  Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.

Authors:  Friederike Mackensen; Carsten Heinz; Matthias D Becker; Arnd Heiligenhaus
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.